{"doc_id": "si-2021-0122-reg-1", "parent_doc_id": "si-2021-0122", "section_id": "reg-1", "section_label": "Regulation 1.", "si_number": "S.I. No. 122 of 2021", "title": "specified in Schedule 1, any of the things mentioned in subsection", "year": 2021, "heading": "1. This Order may be cited as the Misuse of Drugs (Controlled Drugs)", "text_raw": "1. This Order may be cited as the Misuse of Drugs (Controlled Drugs) \n\n(Designation) Order 2021.", "text_norm": "1 order may cited misuse drug (controlled drugs) (designation) order 2021", "start_char": 1149, "end_char": 1248, "source_path": "downloads\\2021\\2021_0122.pdf", "extraction_method": "pdfminer", "checksum": "sha256:15b22691783c1e40c8f6eb66827157701b0741cd6c04d6d73dccd0cab0f67fae", "cross_refs": []}
{"doc_id": "si-2021-0122-reg-2", "parent_doc_id": "si-2021-0122", "section_id": "reg-2", "section_label": "Regulation 2.", "si_number": "S.I. No. 122 of 2021", "title": "specified in Schedule 1, any of the things mentioned in subsection", "year": 2021, "heading": "In this Order, “Act of 1977” means the Misuse of Drugs Act 1977 (No.", "text_raw": "2. \n\nIn this Order, “Act of 1977” means the Misuse of Drugs Act 1977 (No. \n\n12 of 1977).", "text_norm": "2 order act 1977 mean misuse drug act 1977 (no 12 1977)", "start_char": 1248, "end_char": 1339, "source_path": "downloads\\2021\\2021_0122.pdf", "extraction_method": "pdfminer", "checksum": "sha256:15b22691783c1e40c8f6eb66827157701b0741cd6c04d6d73dccd0cab0f67fae", "cross_refs": []}
{"doc_id": "si-2021-0122-reg-3", "parent_doc_id": "si-2021-0122", "section_id": "reg-3", "section_label": "Regulation 3.", "si_number": "S.I. No. 122 of 2021", "title": "specified in Schedule 1, any of the things mentioned in subsection", "year": 2021, "heading": "3. The Misuse of Drugs (Designation) Order 2017 (S.I. No. 174 of 2017) is", "text_raw": "3. The Misuse of Drugs (Designation) Order 2017 (S.I. No. 174 of 2017) is \n\nrevoked.", "text_norm": "3 misuse drug (designation) order 2017 (s.i no 174 2017) revoked", "start_char": 1339, "end_char": 1426, "source_path": "downloads\\2021\\2021_0122.pdf", "extraction_method": "pdfminer", "checksum": "sha256:15b22691783c1e40c8f6eb66827157701b0741cd6c04d6d73dccd0cab0f67fae", "cross_refs": []}
{"doc_id": "si-2021-0122-reg-4", "parent_doc_id": "si-2021-0122", "section_id": "reg-4", "section_label": "Regulation 4.", "si_number": "S.I. No. 122 of 2021", "title": "specified in Schedule 1, any of the things mentioned in subsection", "year": 2021, "heading": "4. The drugs specified in Schedule 1 are designated as drugs to which", "text_raw": "4. The drugs specified in Schedule 1 are designated as drugs to which \n\nsubsection (1) of section 13 of the Act of 1977 applies.", "text_norm": "4 drug specified schedule 1 designated drug subsection (1) section 13 act 1977 applies", "start_char": 1426, "end_char": 1557, "source_path": "downloads\\2021\\2021_0122.pdf", "extraction_method": "pdfminer", "checksum": "sha256:15b22691783c1e40c8f6eb66827157701b0741cd6c04d6d73dccd0cab0f67fae", "cross_refs": []}
{"doc_id": "si-2021-0122-reg-5", "parent_doc_id": "si-2021-0122", "section_id": "reg-5", "section_label": "Regulation 5.", "si_number": "S.I. No. 122 of 2021", "title": "specified in Schedule 1, any of the things mentioned in subsection", "year": 2021, "heading": "5. The purposes set out in Schedule 2 are specified for the purposes of", "text_raw": "5. The purposes set out in Schedule 2 are specified for the purposes of \n\nsubsection (1)(a) of section 13 of the Act of 1977. \n\nNotice of the making of this Statutory Instrument was published in \n“Iris Oifigiúil” of 23rd March, 2021. \n\n \n \n \n \n \n \n \n \n \n \n \n \n\f[122] 3", "text_norm": "5 purpose set schedule 2 specified purpose subsection (1)(a) section 13 act 1977 notice making statutory instrument published iris oifigiuil 23rd march 2021 122 3", "start_char": 1557, "end_char": 1828, "source_path": "downloads\\2021\\2021_0122.pdf", "extraction_method": "pdfminer", "checksum": "sha256:15b22691783c1e40c8f6eb66827157701b0741cd6c04d6d73dccd0cab0f67fae", "cross_refs": []}
{"doc_id": "si-2021-0122-schedule-1", "parent_doc_id": "si-2021-0122", "section_id": "schedule-1", "section_label": "SCHEDULE 1", "si_number": "S.I. No. 122 of 2021", "title": "specified in Schedule 1, any of the things mentioned in subsection", "year": 2021, "heading": null, "text_raw": "SCHEDULE 1", "text_norm": "schedule 1", "start_char": 1828, "end_char": 1841, "source_path": "downloads\\2021\\2021_0122.pdf", "extraction_method": "pdfminer", "checksum": "sha256:15b22691783c1e40c8f6eb66827157701b0741cd6c04d6d73dccd0cab0f67fae", "cross_refs": []}
{"doc_id": "si-2021-0122-reg-1", "parent_doc_id": "si-2021-0122", "section_id": "reg-1", "section_label": "Regulation 1.", "si_number": "S.I. No. 122 of 2021", "title": "specified in Schedule 1, any of the things mentioned in subsection", "year": 2021, "heading": "1. The following substance and products, namely-", "text_raw": "1. The following substance and products, namely- \n\n(a) N-(Adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-\n\ncarboxamide (otherwise known as Clockwork Orange, 5F \nAKB48) \n\nN-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2yl]-1-\n(cyclohexylmethyl)-1H-indazole-3-carboxamide (otherwise \nknown as ADB-CHMINACA) \n\nN-(1-Amino-3,3-dimethyl-1-oxobutan-2yl)-1-(4-fluorobenzyl)1H-indazole-3-carboxamide (otherwise known as ADBFUBINACA) \n\nN-[(2S)-1-Amino-3-methyl-1-oxobutan-2-yl]-1-\n(cyclohexylmethyl)-1H-indazole-3-carboxamide (otherwise \nknown as AB-CHMINACA) \n\nN-[(2S)-1-Amino-3-methyl-1-oxobutan-2yl]-1-pentyl-1Hindazole-3-carboxamide (otherwise known as AB-PINACA) \n\n5-(2-Aminopropyl)indole (otherwise known as 5-IT) \n\n1-(1,3-Benzodioxol-5-yl)-2-(1-pyrrolidinyl)-1-pentanone \n\nN-(1-Benzyl-4-piperidyl)propionanilide \n\n2-(4-Bromo-2,5-dimethoxyphenyl)-N-[(2methoxyphenyl)methyl]ethanamine (otherwise known as 25BNBOMe) \n\n1-(4-Bromofuro[2,3-f][1]benzofuran-8-yl)propan-2-amine \n(otherwise known as BromodragonFLY) \n\nBufotenine \n\nCannabinol, except where contained in Cannabis or cannabis \nresin \n\nCannabinol derivatives, not being dronabinol or its stereoisomers \n\nCannabis (not being a preparation specified in paragraph 5 of Part \n1 of Schedule 4 of the Misuse of Drugs Regulations 2017 (S.I. \nNo. 173 of 2017) or a preparation or product specified in Schedule \n1 to the Misuse of Drugs (Prescription and Control of Supply of \ncannabis for Medical Use) Regulations 2019 (S.I. No. 262 of \n2019)) and permitted for supply pursuant to those Regulations \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\f4 [122] \n\nCannabis resin \n\nCathinone \n\n2-(4-Chloro-2,5-dimethoxyphenyl)-N-[(2methoxyphenyl)methyl]ethanamine (otherwise known as 25CNBOMe) \n\n1-(4-Cyanobutyl)-N-(1-methyl-1-phenylethyl)-1H-indazole-3carboxamide (otherwise known as CUMYL-4CN-BINACA) \n\n1-Cyclohexyl-4-(1,2-diphenylethyl)piperazine (otherwise known \nas MT45) \n\nCoca leaf \n\nConcentrate of poppy straw \n\n3,4-Dichloro-N-[[1-(dimethylamino)cyclohexyl]methyl] \nbenzamide (otherwise known as AH-7921) \n\n3,4-Dichloro-N-(2-dimethylamino-cyclohexyl)-N-methylbenzamide (otherwise known as U-47700) \n\n[2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3de]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone \n\nN,N-Diethyltryptamine \n\n2,5-Dimethoxy-α,4-dimethylphenethylamine \n\nN,N-Dimethyltryptamine \n\n3-Dimethylheptyl-11-hydroxyhexahydrocannabinol \n\nEthyl phenyl(piperidin-2-yl)acetate (otherwise known as \nEthylphenidate) \n\nEticyclidine \n\nEtryptamine \n\n[1-(5-Fluoropentyl)-1H-indol-3-yl](2,2,3,3tetramethylcyclopropyl)methanone (otherwise known as XLR11) \n\n1-(2-Fluorophenyl)-2-methylaminopropan-1-one \n\n1-(3-Fluorophenyl)-2-methylaminopropan-1-one \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\f[122] 5 \n\n1-(4-Fluorophenyl)-2-methylaminopropan-1-one \n\n9-(Hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol \n\n[9-Hydroxy-6-methyl-3-[5-phenylpentan-2-yl]oxy5,6,6a,7,8,9,10,10a-octahydrophenanthridin-1-yl]acetate \n\nN-Hydroxy-tenamphetamine \n\n2-(4-Iodo-2,5-dimethoxyphenyl)-N-[(2methoxyphenyl)methyl]ethanamine (otherwise known as 25INBOMe) \n\nKhat (being the leaves of Catha edulis (Celastraceae)) \n\nLysergamide \n\nLysergide and other N-alkyl derivatives of lysergamide \n\nMescaline \n\nMethcathinone \n\n2-(3-Methoxyphenyl)-2-(ethylamino)cyclohexanone (otherwise \nknown as methoxetamine \n\n1-(4-Methoxyphenyl)-2-(methylamino)propan-1-one \n\nMethyl (2S,4aR,6aR,7R,10aS,10bR)-9-acetyloxy-2-(furan-3-yl)6a,10b-dimethyl-4,10-dioxo-2,4a,5,6,7,8,9,10a-octahydro-1Hbenzo[f]isochromene-7-carboxylate (otherwise known as \nSalvinorin A) and any product, whether natural or otherwise, \nincluding any plant or plant material of any kind or description, \nwhich contains any proportion of the said substance \n\n2-Methylamino-1-(3,4-methylenedioxyphenyl)butan-1-one \n\n2-Methylamino-1-(3,4-methylenedioxyphenyl)propan-1-one \n\n4-Methyl-aminorex \n\nMethyl 2-[[1-(cyclohexylmethyl)indole-3-carbonyl]amino]-3,3dimethylbutanoate (otherwise known as MDMB CHMICA) \n\nMethyl (E)-2-[(2S,3S,7aS,12bS)-3-ethyl-7a-hydroxy-8-methoxy2,3,4,6,7,12b-hexahydro-1H-indolo[2,3a]quinolizin-2-yl]-3methoxyprop-2-enoate (otherwise known as 7Hydroxymitragynine) and any product, whether natural or \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\f6 [122] \n\notherwise, including any plant or plant material of any kind or \ndescription, which contains any proportion of the said substance \n\nMethyl (E)-2-[(2S,3S,12bS)-3-ethyl-8-methoxy1,2,3,4,6,7,12,12b-octahydroindolo[2,3a]quinolizin-2-yl]-3methoxyprop-2-enoate (otherwise known as Mitragynine) and \nany product, whether natural or otherwise, including any plant \nor plant material of any kind or description, which contains any \nproportion of the said substance \n\nMethyl (2S)-2-{[1-(5-fluoropentyl)-1H-indazole-3carbonyl]amino}-3,3-dimethylbutanoate (otherwise known as \n5F-MDMB-PINACA) \n\nMethyl (2S)-2[[1-[(4-fluorophenyl)methyl]indazole-3carbonyl]amino]-3-methylbutanoate (otherwise known as FUBAMB) \n\n4-Methyl-5-(4-methylphenyl)-4,5-dihydro-1,3-oxazol-2-amine \n(otherwise known as 4,4’-DMAR) \n\nα-Methyl-4-(methylthio)phenethylamine \n\n1-(4-Methylphenyl)-2-methylaminopropan-1-one \n\n(1-Pentyl-1H-indol-3-yl)(2,2,3,3tetramethylcyclopropyl)methanone (otherwise known as UR144) \n\nN-Methyl-1-(thiophen-2-yl)propan-2-amine (otherwise known as \nMethiopropamine) \n\nPsilocin \n\nQuinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate \n(otherwise known as Clockwork Orange, PB22) \n\nRaw opium \n\nRolicyclidine \n\nTenocyclidine \n\nN-[1-(2-Thenyl)-4-piperidyl]propionanilide \n\n(b) Any substance (not being bupropion, diethylpropion or \n\npyrovalerone) structurally derived from 2-amino-1-phenyl-1propanone by modification in any of the following ways: \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\f[122] 7 \n\n(i) \n\nby substitution in the phenyl ring to any extent with alkyl, \nalkenyl, alkynyl, alkoxy, alkylthio, alkylenedioxy, \nhaloalkyl or halo substituents, whether or not further \nsubstituted in the phenyl ring by one or more other \nunivalent substituents; \n\n(ii) by substitution at the 2- or 3-position of the propanone side-\n\nchain with an alkyl substituent; \n\n(iii) \n\n by substitution at the nitrogen atom with one or more alkyl \nor dialkyl groups, or by inclusion of the nitrogen atom in a \ncyclic structure. \n\n(c) Any substance structurally derived from 2-amino-1-propanone by \nsubstitution at the 1-position with any monocyclic, or fusedpolycyclic \nring or \nalkylenedioxyphenyl ring system), whether or not the substance \nis further modified in any of the following ways: \n\n(not being a phenyl \n\nring system \n\n(i) \n\nby substitution in the ring system to any extent with alkyl, \nalkenyl, alkynyl, alkoxy, alkylthio, haloalkyl or halo \nsubstituents, whether or not further substituted in the ring \nsystem by one or more other univalent substituents; \n\n(ii) by substitution at the 3-position with an alkyl substituent; \n\n(iii) by substitution at the 2-amino nitrogen atom with one or \nmore alkyl or dialkyl groups, or by inclusion of the 2-amino \nnitrogen atom in a cyclic structure. \n\n(d) Any substance structurally derived from 3-(1-benzoyl)indole or \n3-(1-naphthoyl)indole by modification in any of the following \nways: \n\n(i) \n\nby substitution at the nitrogen atom of the indole ring by \nalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2-(4morpholinyl)ethyl; \n\n(ii) by replacement of one or more hydrogen atoms of any of \nthe substituents referred to in clause (i), with a halo \nsubstituent; \n\nwhether or not further substituted in the indole ring to any extent and \nwhether or not substituted in the phenyl or naphthyl ring to any extent. \n\n(e) \n\n1-Benzylpiperazine or any substance (not being a substance \nspecified in Schedule 3 of the Misuse of Drugs Regulations \n2017) structurally derived from 1-benzylpiperazine or 1phenylpiperazine by modification in any of the following ways: \n\n \n \n \n \n \n \n \n \n \n \n \n \n\f8 [122] \n\n(i) \n\nby substitution at the second nitrogen atom of the \npiperazine ring with alkyl, benzyl, haloalkyl or phenyl \ngroups; \n\n(ii) by substitution in the aromatic ring to any extent with alkyl, \n\nalkoxy, alkylenedioxy, halo or haloalkyl groups. \n\n(f) Any substance (not being a substance specified in Schedule 2 of \nthe Misuse of Drugs Regulations 2017) structurally derived from \nfentanyl by modification in one or more of the following ways, \nthat is to say: \n\n(i) \n\nby replacement of the phenyl portion of the phenethyl group \nby any heteromonocycle whether or not further substituted \nin the heterocycle; \n\n(ii) by substitution in the phenethyl group with alkyl, alkenyl, \n\nalkoxy, hydroxy, halo, haloalkyl, amino or nitro groups; \n\n(iii) by substitution in the piperidine ring with alkyl or alkenyl \n\ngroups; \n\n(iv) by substitution in the aniline ring with alkyl, alkoxy, \n\nalkylenedioxy, halo or haloalkyl groups; \n\n(v) by substitution at the 4-position of the piperidine ring with \nany alkoxycarbonyl or alkoxyalkyl or acyloxy group; \n\n(vi) by replacement of the N-propionyl group by another acyl \n\ngroup. \n\n(g) Any substance structurally derived from 2-(3-\n\nhydroxycyclohexyl)phenol by substitution at the 5-position of \nthe phenolic ring by alkyl, alkenyl, cycloalkylmethyl, \ncycloalkylethyl or 2-(4-morpholinyl)ethyl, whether or not \nfurther substituted in the cyclohexyl ring to any extent. \n\n(h) Any substance structurally derived from 3-(1-naphthoyl)indole \n\nor 1H-indol-3-yl-(1-naphthyl)methane by substitution at the \nnitrogen atom of the indole ring by alkyl, alkenyl, \ncycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl, \nwhether or not further substituted in the indole ring to any extent \nand whether or not substituted in the naphthyl ring to any extent. \n\n(i) Any substance structurally derived from 3-(1-naphthoyl)pyrrole \nby substitution at the nitrogen atom of the pyrrole ring by alkyl, \nalkenyl, cycloalkylmethyl, cycloalkylethyl or 2-(4morpholinyl)ethyl, whether or not further substituted in the \npyrrole ring to any extent and whether or not substituted in the \nnaphthyl ring to any extent. \n\n \n \n \n \n \n \n \n \n \n \n \n \n\f[122] 9 \n\n(j) Any substance structurally derived from 1-(1-\n\nnaphthylmethyl)indene by substitution at the 3-position of the \nindene ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl \nor 2-(4-morpholinyl)ethyl, whether or not further substituted in \nthe indene ring to any extent and whether or not substituted in \nthe naphthyl ring to any extent. \n\n(k) Any substance (not being a substance specified in Schedule 2 of \nthe Misuse of Drugs Regulations 2017) structurally derived from \npethidine by modification in one or more of the following ways, \nthat is to say: \n\n(i) \n\nby replacement of the 1-methyl group by an acyl, alkyl \n(whether or not unsaturated), benzyl or phenethyl group, \nwhether or not further substituted; \n\n(ii) by substitution in the piperidine ring with alkyl or alkenyl \ngroups or with a propano bridge, whether or not further \nsubstituted; \n\n(iii) by substitution in the 4-phenyl ring with alkyl, alkoxy, \n\naryloxy, halo or haloalkyl groups; \n\n(iv) by replacement of the 4-ethoxycarbonyl by any other \nalkoxycarbonyl or any alkoxyalkyl or acyloxy group; \n\n(v) by formation of an N-oxide or of a quaternary base. \n\n(l) Any substance (not being methoxyphenamine) structurally \nderived from phenethylamine, an N-alkyl-phenethylamine, αmethylphenethylamine, an N-alkyl- α-methylphenethylamine, αethylphenethylamine, or an N-alkyl- α- ethylphenethylamine by \nsubstitution in the ring to any extent with alkyl, alkoxy, \nalkylenedioxy or halo substituents, whether or not further \nsubstituted in the ring by one or more other univalent substituents. \n\n(m) Any substance structurally derived from 3-phenylacetylindole \n\nby substitution at the nitrogen atom of the indole ring with alkyl, \nalkenyl, cycloalkylmethyl, cycloalkylethyl or 2-(4morpholinyl)ethyl, whether or not further substituted in the \nindole ring to any extent and whether or not substituted in the \nphenyl ring to any extent. \n\n(n) Any fungus containing any proportion of Psilocin or of an ester \n\nof Psilocin. \n\n(o) 1,2,3,4-Tetrahydronaphthalen-2-amine, 1,2-dihydronaphthalen-\n\n2-amine or 2,3-dihydro-1H-inden-2-amine or any substance \nstructurally derived from 1,2,3,4-tetrahydronaphthalen-2-amine, \n\n \n \n \n \n \n \n \n \n \n \n \n\f10 [122] \n\n1,2-dihydronaphthalen-2-amine or 2,3-dihydro-1H-inden-2amine by modification in any of the following ways: \n\n(i) \n\nby substitution in the phenyl ring to any extent with alkyl, \nalkoxy, alkenyl, alkynyl, alkylthio, alkylenedioxy, \nhaloalkyl, hydroxy or halo substituents, whether or not \nfurther substituted by one or more other univalent \nsubstituents; \n\n(ii) by mono- or di-substitution at the nitrogen atom with alkyl, \nalkenyl, alkynyl or haloalkyl groups or by inclusion of the \nnitrogen atom in a cyclic structure. \n\n(p) Any substance structurally derived from tryptamine or from a \nring-hydroxy tryptamine by substitution at the nitrogen atom of \nthe side-chain with one or more alkyl substituents but no other \nsubstituent.", "text_norm": "1 following substance product namely- (a) n-(adamantan-1-yl)-1-(5-fluoropentyl)-1h-indazole-3- carboxamide (otherwise known clockwork orange 5f akb48) n- (2s)-1-amino-3 3-dimethyl-1-oxobutan-2yl -1- (cyclohexylmethyl)-1h-indazole-3-carboxamide (otherwise known adb-chminaca) n-(1-amino-3 3-dimethyl-1-oxobutan-2yl)-1-(4-fluorobenzyl)1h-indazole-3-carboxamide (otherwise known adbfubinaca) n- (2s)-1-amino-3-methyl-1-oxobutan-2-yl -1- (cyclohexylmethyl)-1h-indazole-3-carboxamide (otherwise known ab-chminaca) n- (2s)-1-amino-3-methyl-1-oxobutan-2yl -1-pentyl-1hindazole-3-carboxamide (otherwise known ab-pinaca) 5-(2-aminopropyl)indole (otherwise known 5-it) 1-(1 3-benzodioxol-5-yl)-2-(1-pyrrolidinyl)-1-pentanone n-(1-benzyl-4-piperidyl)propionanilide 2-(4-bromo-2 5-dimethoxyphenyl)-n- (2methoxyphenyl)methyl ethanamine (otherwise known 25bnbome) 1-(4-bromofuro 2 3-f 1 benzofuran-8-yl)propan-2-amine (otherwise known bromodragonfly) bufotenine cannabinol except contained cannabis cannabis resin cannabinol derivative dronabinol stereoisomers cannabis (not preparation specified paragraph 5 part 1 schedule 4 misuse drug regulation 2017 (s.i no 173 2017) preparation product specified schedule 1 misuse drug (prescription control supply cannabis medical use) regulation 2019 (s.i no 262 2019)) permitted supply pursuant regulation 4 122 cannabis resin cathinone 2-(4-chloro-2 5-dimethoxyphenyl)-n- (2methoxyphenyl)methyl ethanamine (otherwise known 25cnbome) 1-(4-cyanobutyl)-n-(1-methyl-1-phenylethyl)-1h-indazole-3carboxamide (otherwise known cumyl-4cn-binaca) 1-cyclohexyl-4-(1 2-diphenylethyl)piperazine (otherwise known mt45) coca leaf concentrate poppy straw 3 4-dichloro-n- 1-(dimethylamino)cyclohexyl methyl benzamide (otherwise known ah-7921) 3 4-dichloro-n-(2-dimethylamino-cyclohexyl)-n-methylbenzamide (otherwise known u-47700) 2 3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo 1 2 3de -1 4-benzoxazin-6-yl -1-naphthalenylmethanone n n-diethyltryptamine 2 5-dimethoxy-a 4-dimethylphenethylamine n n-dimethyltryptamine 3-dimethylheptyl-11-hydroxyhexahydrocannabinol ethyl phenyl(piperidin-2-yl)acetate (otherwise known ethylphenidate) eticyclidine etryptamine 1-(5-fluoropentyl)-1h-indol-3-yl (2 2 3 3tetramethylcyclopropyl)methanone (otherwise known xlr11) 1-(2-fluorophenyl)-2-methylaminopropan-1-one 1-(3-fluorophenyl)-2-methylaminopropan-1-one 122 5 1-(4-fluorophenyl)-2-methylaminopropan-1-one 9-(hydroxymethyl)-6 6-dimethyl-3-(2-methyloctan-2-yl)6a 7 10 10a-tetrahydrobenzo c chromen-1-ol 9-hydroxy-6-methyl-3- 5-phenylpentan-2-yl oxy5 6 6a 7 8 9 10 10a-octahydrophenanthridin-1-yl acetate n-hydroxy-tenamphetamine 2-(4-iodo-2 5-dimethoxyphenyl)-n- (2methoxyphenyl)methyl ethanamine (otherwise known 25inbome) khat (being leaf catha edulis (celastraceae)) lysergamide lysergide n-alkyl derivative lysergamide mescaline methcathinone 2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone (otherwise known methoxetamine 1-(4-methoxyphenyl)-2-(methylamino)propan-1-one methyl (2s 4ar 6ar 7r 10as 10br)-9-acetyloxy-2-(furan-3-yl)6a 10b-dimethyl-4 10-dioxo-2 4a 5 6 7 8 9 10a-octahydro-1hbenzo f isochromene-7-carboxylate (otherwise known salvinorin a) product whether natural otherwise including plant plant material kind description contains proportion said substance 2-methylamino-1-(3 4-methylenedioxyphenyl)butan-1-one 2-methylamino-1-(3 4-methylenedioxyphenyl)propan-1-one 4-methyl-aminorex methyl 2- 1-(cyclohexylmethyl)indole-3-carbonyl amino -3 3dimethylbutanoate (otherwise known mdmb chmica) methyl (e)-2- (2s 3 7as 12bs)-3-ethyl-7a-hydroxy-8-methoxy2 3 4 6 7 12b-hexahydro-1h-indolo 2 3a quinolizin-2-yl -3methoxyprop-2-enoate (otherwise known 7hydroxymitragynine) product whether natural 6 122 otherwise including plant plant material kind description contains proportion said substance methyl (e)-2- (2s 3 12bs)-3-ethyl-8-methoxy1 2 3 4 6 7 12 12b-octahydroindolo 2 3a quinolizin-2-yl -3methoxyprop-2-enoate (otherwise known mitragynine) product whether natural otherwise including plant plant material kind description contains proportion said substance methyl (2s)-2- 1-(5-fluoropentyl)-1h-indazole-3carbonyl amino -3 3-dimethylbutanoate (otherwise known 5f-mdmb-pinaca) methyl (2s)-2 1- (4-fluorophenyl)methyl indazole-3carbonyl amino -3-methylbutanoate (otherwise known fubamb) 4-methyl-5-(4-methylphenyl)-4 5-dihydro-1 3-oxazol-2-amine (otherwise known 4 4 -dmar) a-methyl-4-(methylthio)phenethylamine 1-(4-methylphenyl)-2-methylaminopropan-1-one (1-pentyl-1h-indol-3-yl)(2 2 3 3tetramethylcyclopropyl)methanone (otherwise known ur144) n-methyl-1-(thiophen-2-yl)propan-2-amine (otherwise known methiopropamine) psilocin quinolin-8-yl 1-(5-fluoropentyl)-1h-indole-3-carboxylate (otherwise known clockwork orange pb22) raw opium rolicyclidine tenocyclidine n- 1-(2-thenyl)-4-piperidyl propionanilide (b) substance (not bupropion diethylpropion pyrovalerone) structurally derived 2-amino-1-phenyl-1propanone modification following way 122 7 (i) substitution phenyl ring extent alkyl alkenyl alkynyl alkoxy alkylthio alkylenedioxy haloalkyl halo substituents whether substituted phenyl ring one univalent substituents (ii) substitution 2- 3-position propanone side- chain alkyl substituent (iii) substitution nitrogen atom one alkyl dialkyl group inclusion nitrogen atom cyclic structure (c) substance structurally derived 2-amino-1-propanone substitution 1-position monocyclic fusedpolycyclic ring alkylenedioxyphenyl ring system) whether substance modified following way (not phenyl ring system (i) substitution ring system extent alkyl alkenyl alkynyl alkoxy alkylthio haloalkyl halo substituents whether substituted ring system one univalent substituents (ii) substitution 3-position alkyl substituent (iii) substitution 2-amino nitrogen atom one alkyl dialkyl group inclusion 2-amino nitrogen atom cyclic structure (d) substance structurally derived 3-(1-benzoyl)indole 3-(1-naphthoyl)indole modification following way (i) substitution nitrogen atom indole ring alkyl alkenyl cycloalkylmethyl cycloalkylethyl 2-(4morpholinyl)ethyl (ii) replacement one hydrogen atom substituents referred clause (i) halo substituent whether substituted indole ring extent whether substituted phenyl naphthyl ring extent (e) 1-benzylpiperazine substance (not substance specified schedule 3 misuse drug regulation 2017) structurally derived 1-benzylpiperazine 1phenylpiperazine modification following way 8 122 (i) substitution second nitrogen atom piperazine ring alkyl benzyl haloalkyl phenyl group (ii) substitution aromatic ring extent alkyl alkoxy alkylenedioxy halo haloalkyl group (f) substance (not substance specified schedule 2 misuse drug regulation 2017) structurally derived fentanyl modification one following way say (i) replacement phenyl portion phenethyl group heteromonocycle whether substituted heterocycle (ii) substitution phenethyl group alkyl alkenyl alkoxy hydroxy halo haloalkyl amino nitro group (iii) substitution piperidine ring alkyl alkenyl group (iv) substitution aniline ring alkyl alkoxy alkylenedioxy halo haloalkyl group (v) substitution 4-position piperidine ring alkoxycarbonyl alkoxyalkyl acyloxy group (vi) replacement n-propionyl group another acyl group (g) substance structurally derived 2-(3- hydroxycyclohexyl)phenol substitution 5-position phenolic ring alkyl alkenyl cycloalkylmethyl cycloalkylethyl 2-(4-morpholinyl)ethyl whether substituted cyclohexyl ring extent (h) substance structurally derived 3-(1-naphthoyl)indole 1h-indol-3-yl-(1-naphthyl)methane substitution nitrogen atom indole ring alkyl alkenyl cycloalkylmethyl cycloalkylethyl 2-(4-morpholinyl)ethyl whether substituted indole ring extent whether substituted naphthyl ring extent (i) substance structurally derived 3-(1-naphthoyl)pyrrole substitution nitrogen atom pyrrole ring alkyl alkenyl cycloalkylmethyl cycloalkylethyl 2-(4morpholinyl)ethyl whether substituted pyrrole ring extent whether substituted naphthyl ring extent 122 9 (j) substance structurally derived 1-(1- naphthylmethyl)indene substitution 3-position indene ring alkyl alkenyl cycloalkylmethyl cycloalkylethyl 2-(4-morpholinyl)ethyl whether substituted indene ring extent whether substituted naphthyl ring extent (k) substance (not substance specified schedule 2 misuse drug regulation 2017) structurally derived pethidine modification one following way say (i) replacement 1-methyl group acyl alkyl (whether unsaturated) benzyl phenethyl group whether substituted (ii) substitution piperidine ring alkyl alkenyl group propano bridge whether substituted (iii) substitution 4-phenyl ring alkyl alkoxy aryloxy halo haloalkyl group (iv) replacement 4-ethoxycarbonyl alkoxycarbonyl alkoxyalkyl acyloxy group (v) formation n-oxide quaternary base (l) substance (not methoxyphenamine) structurally derived phenethylamine n-alkyl-phenethylamine amethylphenethylamine n-alkyl- a-methylphenethylamine aethylphenethylamine n-alkyl- a- ethylphenethylamine substitution ring extent alkyl alkoxy alkylenedioxy halo substituents whether substituted ring one univalent substituents (m) substance structurally derived 3-phenylacetylindole substitution nitrogen atom indole ring alkyl alkenyl cycloalkylmethyl cycloalkylethyl 2-(4morpholinyl)ethyl whether substituted indole ring extent whether substituted phenyl ring extent (n) fungus containing proportion psilocin ester psilocin (o) 1 2 3 4-tetrahydronaphthalen-2-amine 1 2-dihydronaphthalen- 2-amine 2 3-dihydro-1h-inden-2-amine substance structurally derived 1 2 3 4-tetrahydronaphthalen-2-amine 10 122 1 2-dihydronaphthalen-2-amine 2 3-dihydro-1h-inden-2amine modification following way (i) substitution phenyl ring extent alkyl alkoxy alkenyl alkynyl alkylthio alkylenedioxy haloalkyl hydroxy halo substituents whether substituted one univalent substituents (ii) mono- di-substitution nitrogen atom alkyl alkenyl alkynyl haloalkyl group inclusion nitrogen atom cyclic structure (p) substance structurally derived tryptamine ring-hydroxy tryptamine substitution nitrogen atom side-chain one alkyl substituents substituent", "start_char": 1841, "end_char": 14823, "source_path": "downloads\\2021\\2021_0122.pdf", "extraction_method": "pdfminer", "checksum": "sha256:15b22691783c1e40c8f6eb66827157701b0741cd6c04d6d73dccd0cab0f67fae", "cross_refs": []}
{"doc_id": "si-2021-0122-reg-2", "parent_doc_id": "si-2021-0122", "section_id": "reg-2", "section_label": "Regulation 2.", "si_number": "S.I. No. 122 of 2021", "title": "specified in Schedule 1, any of the things mentioned in subsection", "year": 2021, "heading": "2. Any stereoisomeric form of a substance specified in paragraph 1.", "text_raw": "2. Any stereoisomeric form of a substance specified in paragraph 1.", "text_norm": "2 stereoisomeric form substance specified paragraph 1", "start_char": 14823, "end_char": 14893, "source_path": "downloads\\2021\\2021_0122.pdf", "extraction_method": "pdfminer", "checksum": "sha256:15b22691783c1e40c8f6eb66827157701b0741cd6c04d6d73dccd0cab0f67fae", "cross_refs": []}
{"doc_id": "si-2021-0122-reg-3", "parent_doc_id": "si-2021-0122", "section_id": "reg-3", "section_label": "Regulation 3.", "si_number": "S.I. No. 122 of 2021", "title": "specified in Schedule 1, any of the things mentioned in subsection", "year": 2021, "heading": "3. Any ester or ether of a substance specified in paragraph 1 or 2.", "text_raw": "3. Any ester or ether of a substance specified in paragraph 1 or 2.", "text_norm": "3 ester ether substance specified paragraph 1 2", "start_char": 14893, "end_char": 14963, "source_path": "downloads\\2021\\2021_0122.pdf", "extraction_method": "pdfminer", "checksum": "sha256:15b22691783c1e40c8f6eb66827157701b0741cd6c04d6d73dccd0cab0f67fae", "cross_refs": []}
{"doc_id": "si-2021-0122-reg-4", "parent_doc_id": "si-2021-0122", "section_id": "reg-4", "section_label": "Regulation 4.", "si_number": "S.I. No. 122 of 2021", "title": "specified in Schedule 1, any of the things mentioned in subsection", "year": 2021, "heading": "4. Any salt of a substance specified in any of paragraphs 1, 2 or 3.", "text_raw": "4. Any salt of a substance specified in any of paragraphs 1, 2 or 3.", "text_norm": "4 salt substance specified paragraph 1 2 3", "start_char": 14963, "end_char": 15034, "source_path": "downloads\\2021\\2021_0122.pdf", "extraction_method": "pdfminer", "checksum": "sha256:15b22691783c1e40c8f6eb66827157701b0741cd6c04d6d73dccd0cab0f67fae", "cross_refs": []}
{"doc_id": "si-2021-0122-reg-5", "parent_doc_id": "si-2021-0122", "section_id": "reg-5", "section_label": "Regulation 5.", "si_number": "S.I. No. 122 of 2021", "title": "specified in Schedule 1, any of the things mentioned in subsection", "year": 2021, "heading": "5. Any preparation or other product containing any proportion of a", "text_raw": "5. Any preparation or other product containing any proportion of a \nsubstance or product specified in any of paragraphs 1, 2, 3 or 4, not being \na preparation specified in Schedule 5 of the Misuse of Drugs Regulations", "text_norm": "5 preparation product containing proportion substance product specified paragraph 1 2 3 4 preparation specified schedule 5 misuse drug regulation", "start_char": 15034, "end_char": 15253, "source_path": "downloads\\2021\\2021_0122.pdf", "extraction_method": "pdfminer", "checksum": "sha256:15b22691783c1e40c8f6eb66827157701b0741cd6c04d6d73dccd0cab0f67fae", "cross_refs": []}
{"doc_id": "si-2021-0122-reg-2017", "parent_doc_id": "si-2021-0122", "section_id": "reg-2017", "section_label": "Regulation 2017.", "si_number": "S.I. No. 122 of 2021", "title": "specified in Schedule 1, any of the things mentioned in subsection", "year": 2021, "heading": "[122] 11", "text_raw": "2017. \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n\f[122] 11", "text_norm": "2017 122 11", "start_char": 15253, "end_char": 15299, "source_path": "downloads\\2021\\2021_0122.pdf", "extraction_method": "pdfminer", "checksum": "sha256:15b22691783c1e40c8f6eb66827157701b0741cd6c04d6d73dccd0cab0f67fae", "cross_refs": []}
{"doc_id": "si-2021-0122-schedule-2", "parent_doc_id": "si-2021-0122", "section_id": "schedule-2", "section_label": "SCHEDULE 2", "si_number": "S.I. No. 122 of 2021", "title": "specified in Schedule 1, any of the things mentioned in subsection", "year": 2021, "heading": "The following purposes, namely:-", "text_raw": "SCHEDULE 2 \n\nThe following purposes, namely:- \n\n(a) \n\n(b) \n\nresearch, forensic analysis or use as an essential intermediate or \nstarting material in an industrial manufacturing process; \n\nthe growing of hemp from seed varieties specified, by the \nCommission of the European Communities, as being eligible for \nthe purposes of Article 1 of Regulation (EU) No. 1307/2013 of \nthe European Parliament and of the Council of 17 December \n20131; \n\nsubject to such licensing provision under the Act of 1977 and the Regulations \nmade thereunder as are applicable. \n\nGIVEN under my Official Seal, \n\n18 March, 2021. \n\nSTEPHEN DONNELLY, \nMinister for Health. \n\n1 OJ No L 347, 20.12.2013, p. 608 \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\f12 [122]", "text_norm": "schedule 2 following purpose namely - (a) (b) research forensic analysis use essential intermediate starting material industrial manufacturing process growing hemp seed variety specified commission european community eligible purpose article 1 regulation (eu) no 1307 2013 european parliament council 17 december 20131 subject licensing provision act 1977 regulation made thereunder applicable given official seal 18 march 2021 stephen donnelly minister health 1 oj l 347 20.12.2013 p 608 12 122", "start_char": 15299, "end_char": 16046, "source_path": "downloads\\2021\\2021_0122.pdf", "extraction_method": "pdfminer", "checksum": "sha256:15b22691783c1e40c8f6eb66827157701b0741cd6c04d6d73dccd0cab0f67fae", "cross_refs": []}
{"doc_id": "si-2021-0122-explanatory-note", "parent_doc_id": "si-2021-0122", "section_id": "explanatory-note", "section_label": "EXPLANATORY NOTE", "si_number": "S.I. No. 122 of 2021", "title": "specified in Schedule 1, any of the things mentioned in subsection", "year": 2021, "heading": "(This note is not part of the Instrument and does not purport to be a legal", "text_raw": "EXPLANATORY NOTE \n\n(This note is not part of the Instrument and does not purport to be a legal \ninterpretation). \n\nThe purpose of this Order is to amend the Misuse of Drugs (Designation) Order \n2017 by inserting into Schedule 1 to that Order the following: \n\nN-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2yl]-1-(cyclohexylmethyl)-1Hindazole-3-carboxamide (otherwise known as ADB-CHMINACA) \n\nN-(1-Amino-3,3-dimethyl-1-oxobutan-2yl)-1-(4-fluorobenzyl)-1H-indazole-3carboxamide (otherwise known as ADB-FUBINACA) \n\nN-[(2S)-1-Amino-3-methyl-1-oxobutan-2-yl]-1-(cyclohexylmethyl)-1Hindazole-3-carboxamide (otherwise known as AB-CHMINACA) \n\nN-[(2S)-1-Amino-3-methyl-1-oxobutan-2yl]-1-pentyl-1H-indazole-3carboxamide (otherwise known as AB-PINACA) \n\n1-(4-Cyanobutyl)-N-(1-methyl-1-phenylethyl)-1H-indazole-3-carboxamide \n(otherwise known as CUMYL-4CN-BINACA) \n\nMethyl (2S)-2-{[1-(5-fluoropentyl)-1H-indazole-3-carbonyl]amino}-3,3dimethylbutanoate (otherwise known as 5F-MDMB-PINACA) \n\nMethyl (2S)-2[[1-[(4-fluorophenyl)methyl]indazole-3-carbonyl]amino]-3methylbutanoate (otherwise known as FUB-AMB) \n\n(1-Pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (otherwise \nknown as UR-144) \n\nThis Order may be cited as the Misuse of Drugs Act 1977 (Controlled Drugs) \n(Designation) Order 2021. \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\f[122] 13 \n\nBAILE ÁTHA CLIATH \nARNA FHOILSIÚ AG OIFIG AN tSOLÁTHAIR \nLe ceannach díreach ó \nFOILSEACHÁIN RIALTAIS, \n52 FAICHE STIABHNA, BAILE ÁTHA CLIATH 2, \nD02 DR67. \n\nTeil: 076 110 6834 \nr-post: publications@opw.ie \n—————— \n\nDUBLIN \nPUBLISHED BY THE STATIONERY OFFICE \nTo be purchased from \nGOVERNMENT PUBLICATIONS, \n52 ST. STEPHEN'S GREEN, DUBLIN 2, \nD02 DR67. \n\nTel: 076 110 6834 \nE-mail: publications@opw.ie \n—————— \n\n€3.50 \n\n(DH-197) 75. 3/21. Propylon.", "text_norm": "explanatory note (this note part instrument purport legal interpretation) purpose order amend misuse drug (designation) order 2017 inserting schedule 1 order following n- (2s)-1-amino-3 3-dimethyl-1-oxobutan-2yl -1-(cyclohexylmethyl)-1hindazole-3-carboxamide (otherwise known adb-chminaca) n-(1-amino-3 3-dimethyl-1-oxobutan-2yl)-1-(4-fluorobenzyl)-1h-indazole-3carboxamide (otherwise known adb-fubinaca) n- (2s)-1-amino-3-methyl-1-oxobutan-2-yl -1-(cyclohexylmethyl)-1hindazole-3-carboxamide (otherwise known ab-chminaca) n- (2s)-1-amino-3-methyl-1-oxobutan-2yl -1-pentyl-1h-indazole-3carboxamide (otherwise known ab-pinaca) 1-(4-cyanobutyl)-n-(1-methyl-1-phenylethyl)-1h-indazole-3-carboxamide (otherwise known cumyl-4cn-binaca) methyl (2s)-2- 1-(5-fluoropentyl)-1h-indazole-3-carbonyl amino -3 3dimethylbutanoate (otherwise known 5f-mdmb-pinaca) methyl (2s)-2 1- (4-fluorophenyl)methyl indazole-3-carbonyl amino -3methylbutanoate (otherwise known fub-amb) (1-pentyl-1h-indol-3-yl)(2 2 3 3-tetramethylcyclopropyl)methanone (otherwise known ur-144) order may cited misuse drug act 1977 (controlled drugs) (designation) order 2021 122 13 baile atha cliath arna fhoilsiu ag oifig tsolathair le ceannach direach foilseachain rialtais 52 faiche stiabhna baile atha cliath 2 d02 dr67 teil 076 110 6834 r-post publication opw.ie ------------ dublin published stationery office purchased government publication 52 st stephen green dublin 2 d02 dr67 tel 076 110 6834 e-mail publication opw.ie ------------ eur3.50 (dh-197) 75 3 21 propylon", "start_char": 16046, "end_char": 17825, "source_path": "downloads\\2021\\2021_0122.pdf", "extraction_method": "pdfminer", "checksum": "sha256:15b22691783c1e40c8f6eb66827157701b0741cd6c04d6d73dccd0cab0f67fae", "cross_refs": []}
